CAMBRIDGE, Mass., Oct. 12, 2023 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company developing medicines for broad populations of cancer patients with an initial aim to develop a universal-RAS therapy, today presented encouraging preclinical data for both IMM-1-104, its lead clinical-stage program, and IMM-6-415 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, taking place October 11-15, 2023 in Boston, Massachusetts.
“Today we are sharing new preclinical data that further support the potential of IMM-1-104 and IMM-6-415 as single agents and in combination regimens across a wide array of MAPK-driven tumor types, including those with RAS or RAF mutations,” said Ben Zeskind, Ph.D., Co-founder and Chief Executive Officer of Immuneering. “Our goal is to help broad populations of cancer patients achieve better responses. The opportunity to advance our promising monotherapy programs while also targeting new opportunities in combination therapy could position us to develop safer and more effective treatment options for an even broader range of patients. Today’s findings add cytotoxic agents and RAF inhibitors to the list of promising combinations, building on our previously disclosed data supporting combinations with KRAS-G12C inhibitors and immuno-oncology agents. Tolerability is important for successful combinations, and we designed IMM-1-104 and IMM-6-415 with a unique deep cyclic inhibition mechanism that aims to provide both good tolerability and broad activity in MAPK-driven tumors. We believe that IMM-1-104 and IMM-6-415, alone, and in combination with other agents, have the potential to bring significant benefit to broad populations of patients with RAS or RAF mutant cancers.”
Details for the poster presentations are as follows:
Title: Predicting activity of IMM-1-104 as single agent and in combination for patients with RAS or RAF mutant tumors
Title: Deep Cyclic Inhibition of the MAPK pathway with IMM-6-415, alone and in combination with encorafenib, demonstrates anti-tumor activity and tolerability in RAF mutant tumors in vivo
“In addition to RAS mutant disease, we are optimistic about the potential clinical translation and therapeutic potential for IMM-6-415 in RAF mutant disease,” said Brett Hall, Ph.D., Chief Scientific Officer of Immuneering. “Moreover, we believe IMM-6-415’s short half-life of approximately 20 minutes in mice, coupled with its superior preclinical activity compared to a currently available MEK inhibitor in RAF mutant models, may reinforce the opportunity for combination therapy of IMM-6-415 with RAF inhibitors in the clinic. We are also excited about the preclinical data we released today showing that IMM-1-104 can enhance the activity of cytotoxic agents that are currently used as standard of care treatment for pancreatic cancer patients in the first- or second-line setting.”
These abstracts are available on the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics website. Posters will be available on the “Publications” section of Immuneering’s website at https://immuneering.com/publications.
About IMM-1-104
IMM-1-104 aims to achieve universal-RAS activity that selectively impacts cancer cells to a greater extent than healthy cells, through deep cyclic inhibition of the MAPK pathway with once-daily oral dosing. IMM-1-104 is currently being evaluated in the Phase 1b dose expansion portion of a Phase 1/2a study in patients with advanced solid tumors harboring RAS mutations for whom there are limited treatment options (NCT05585320).
About IMM-6-415
IMM-6-415 targets RAF and RAS mutant tumors through deep cyclic inhibition of the MAPK pathway with an accelerated cadence. IMM-6-415 was designed with unique drug-like properties that distinguish it from other programs in the Immuneering pipeline, including a shorter half-life than IMM-1-104 which gives IMM-6-415 an accelerated cadence relative to the once-daily dosing of IMM-1-104. IMM-6-415 is being developed for monotherapy and combination applications in oncology, including the ability to enhance immune mediated therapy in certain settings. An IND filing for IMM-6-415 is expected in the fourth quarter of 2023.
About Immuneering Corporation
Immuneering is a clinical-stage oncology company developing medicines for broad populations of cancer patients with an initial aim to develop a universal-RAS therapy. The Company aims to achieve universal activity through deep cyclic inhibition of the MAPK pathway, impacting cancer cells while sparing healthy cells. Immuneering’s lead product candidate, IMM-1-104, is in a Phase 1/2a study in patients with advanced solid tumors harboring RAS mutations. The company’s development pipeline also includes IMM-6-415, a universal-MAPK program, as well as several early-stage programs. For more information, please visit www.immuneering.com.
Forward-Looking Statements
This press release contains forward-looking statements, including within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements concerning: the expected design, timing, enrollment and advancement of, and data results from, preclinical studies and clinical trials involving our product candidates; the potential of our product candidates to be used as monotherapies and / or in combination with other therapeutic agents, including to treat RAS or RAF mutant diseases; and the clinical development of IMM-1-104 and anticipated filing of an IND for IMM-6-415.
These forward-looking statements are based on management’s current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: the risks inherent in oncology drug research and development, including target discovery, target validation, lead compound identification, and lead compound optimization; we have incurred significant losses, are not currently profitable and may never become profitable; our projected cash runway; our need for additional funding; our unproven approach to therapeutic intervention; our ability to address regulatory questions and the uncertainties relating to regulatory filings, reviews and approvals; the lengthy, expensive, and uncertain process of clinical drug development, including potential delays in or failure to obtain regulatory approvals; our reliance on third parties and collaborators to conduct our clinical trials, manufacture our product candidates, and develop and commercialize our product candidates, if approved; failure to compete successfully against other drug companies; protection of our proprietary technology and the confidentiality of our trade secrets; potential lawsuits for, or claims of, infringement of third-party intellectual property or challenges to the ownership of our intellectual property; our patents being found invalid or unenforceable; costs and resources of operating as a public company; and unfavorable or no analyst research or reports.
These and other important factors discussed under the caption "Risk Factors" in our Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2023, and our other reports filed with the United States Securities and Exchange Commission, could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management's estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, except as required by law, we disclaim any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.
Media Contact:
Gina Nugent
Nugent Communications
617-460-3579
This email address is being protected from spambots. You need JavaScript enabled to view it.
Investor Contacts:
Laurence Watts
Gilmartin Group
619-916-7620
This email address is being protected from spambots. You need JavaScript enabled to view it.
or
Kiki Patel, PharmD
Gilmartin Group
332-895-3225
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$1.97 |
Daily Change: | -0.01 -0.61 |
Daily Volume: | 243,325 |
Market Cap: | US$58.350M |
October 15, 2024 August 29, 2024 August 06, 2024 July 31, 2024 |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREAmneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB